GRI Bio, Inc. cash flow to debt ratio of -14.35K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

GRI Bio, Inc.'s free cash flow has decreased 18.33% from $-8.61M last year to $-10.19M, signaling decreasing performance

GRI Bio, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

GRI Bio, Inc.'s debt has decreased relative to shareholder equity from 0.03 last year to 0.01 today, signaling strengthened financials

GRI Bio, Inc. has a net cash position, so leverage is healthy.

GRI Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

GRI Bio, Inc.'s profit margin has increased (-100.00%) in the last year from -36.41% to 0.00%, signaling increasing performance

GRI Bio, Inc.'s short-term assets of $8.59M exceed its short-term liabilities of $2.64M

GRI Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

GRI Bio, Inc.'s return on equity of -199.52%, is lower than 15.00%, indicating bad performance

GRI Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

GRI Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

GRI Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

GRI Bio, Inc. has negative free cash flow, indicating cash burn

GRI Bio, Inc.'s yearly earnings has decreased 45.68% since last year from $-8.21M to $-11.96M, signaling decreasing performance

GRI Bio, Inc.'s yearly revenue has decreased 100.00% since last year from $22.54M to $0.00, signaling decreasing performance

ROIC -103.07% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

GRI Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

GRI Bio, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

GRI Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

GRI Bio, Inc. has insufficient data to evaluate this check.

GRI Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GRI Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

GRI Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

GRI Bio, Inc. has insufficient data to evaluate this check.

GRI Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GRI Bio, Inc. has a price-to-book ratio of 0.20x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

GRI Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue